This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi, Risankizumab...
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab,...
After its depression candidate failed a phase 3 trial and disappointed analysts,...
Human medicines European public assessment report (EPAR): Fasenra, benralizumab,...
Astellas is shifting its investment focus toward more established modalities and...
Union list of critical medicines: eXtended EudraVigilance Medicinal Product Dict...
Reports of impending layoffs, a buyout offer, and a return-to-office mandate hav...
Herbal medicinal product: Anisi aetheroleumArray, C: ongoing call for scientific...
Herbal medicinal product: Valerianae radixArray, C: ongoing call for scientific ...
Herbal medicinal product: Valerianae aetheroleumArray, C: ongoing call for scien...
Herbal medicinal product: Salviae officinalis foliumArray, C: ongoing call for s...
Herbal medicinal product: Centaurii herbaArray, C: ongoing call for scientific data
Herbal medicinal product: Anisi fructusArray, C: ongoing call for scientific data
Herbal medicinal product: Hyperici herbaArray,Array, D: Draft under discussion
Procedures for monograph and list entry establishment
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights find...
Herbal medicinal product: Anisi aetheroleumArray, F: Assessment finalised
Plus more health news you need to read this morning.
Herbal medicinal product: Valerianae radixArray, F: Assessment finalised
Herbal medicinal product: Valerianae aetheroleumArray, F: Assessment finalised
Herbal medicinal product: Salviae officinalis foliumArray, F: Assessment finalised